Dna Testing Centers Corp Receivables Turnover Ratio (DNAT), from the fourth quarter 2018 to the fourth quarter 2017 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Dna Testing Centers Corp  (DNAT)
 

Dna Testing Centers Accounts Receivables Turnover Ratio from the fourth quarter 2018 to the fourth quarter 2017

Quarterly Results, Trends, Rankings, Statistics


Dna Testing Centers Corp's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2018 to a ratio of 33.57, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the fourth quarter 2018. Average receivable collection period, for the Dna Testing Centers in Dec 31 2018 quarter, has decreased to 11 days, compared to 12 days, in the Dec 31 2017 quarter.

If we take a look into Healthcare sector 125 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2018 from 237 to 1474.

What is Receivable Turnover Ratio?
What is Dna Testing Centers Corp Selling?


What is Receivable Turnover Ratio?





DNAT Receivables Turnover Ratio (Dec 31 2018)
IV. Quarter
(Dec 31 2017)
IV. Quarter
(Sep 30 2017)
III. Quarter
(Jun 30 2017)
II. Quarter
(Mar 31 2017)
I. Quarter
Y / Y Receivable Change -91.6 % - -74.85 % 548.55 % 1758.54 %
Y / Y Revenue Change - -47.89 % 0.77 % 185.45 % 351.64 %
Receivable Turnover Ratio (TTM) 33.57 30.16 24.44 17.02 16
DNAT's Total Ranking # 1474 # 237 # # #
Accounts Receivable average collection period days 11 12 15 21 23
Seq. Receivable Change - - -41.44 % -26.38 % 26.47 %
Seq. Revenue Change - -50.4 % -30.84 % 6.63 % 42.47 %


Receivable Turnover Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 3
Healthcare Sector # 126
Overall Market # 1474

Receivable Turnover Ratio Statistics
High Average Low
4.84 2.52 0.92
(Jun 30 2017)   (Jun 30 2016)






Financial Statements
Dna Testing Centers's Accounts Receivable $ 0 Millions Visit DNAT's Balance sheet
Dna Testing Centers's Sales TTM $ 0 Millions Visit DNAT's Income Statement
Sources of DNAT's Revenues Visit DNAT's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
DNAT's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
DNAT's Growth Rates DNAT's Roa DNAT's Inventory Turnover Ratio DNAT's Dividend Comparisons
DNAT's Profitability Ratios DNAT's Roi DNAT's Asset Turnover Ratio DNAT's Dividend Growth
DNAT's Valuation Ratios DNAT's Roe DNAT's Financial Strength Ratios DNAT's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2018, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Dec 31 2018 Receivable at quarter ending Dec 31 2018
Siga Technologies Inc  276.90 $ 477.053  Millions$ 1.723  Millions
Arrowhead Pharmaceuticals Inc   275.74 $ 47.290  Millions$ 0.172  Millions
Medicure Inc   249.25 $ 22.298  Millions$ 0.089  Millions
Diversicare Healthcare Services Inc   245.78 $ 563.462  Millions$ 2.293  Millions
Zymeworks Inc   220.22 $ 53.019  Millions$ 0.241  Millions
Scorpius Holdings inc   199.05 $ 5.794  Millions$ 0.029  Millions
Applied Genetic Technologies Corporation  171.01 $ 28.987  Millions$ 0.170  Millions
U s Stem Cell Inc   154.18 $ 6.701  Millions$ 0.043  Millions
Sophiris Bio Inc.  102.46 $ 0.333  Millions$ 0.003  Millions
Hutchmed china Limited  93.79 $ 214.109  Millions$ 2.283  Millions
Editas Medicine Inc   93.52 $ 31.937  Millions$ 0.342  Millions
Affimed N v   91.29 $ 26.583  Millions$ 0.291  Millions
Innovage Holding Corp   85.61 $ 23.990  Millions$ 0.280  Millions
Lifevantage Corp  84.22 $ 218.371  Millions$ 2.593  Millions
Reliv International Inc  83.23 $ 36.116  Millions$ 0.434  Millions
Decoy Therapeutics Inc   81.53 $ 1.241  Millions$ 0.015  Millions
Chemocentryx Inc.  80.59 $ 85.750  Millions$ 1.064  Millions
Pfenex Inc   76.29 $ 14.857  Millions$ 0.195  Millions
Arcus Biosciences Inc   75.25 $ 8.353  Millions$ 0.111  Millions
Ayala Pharmaceuticals Inc   62.32 $ 23.696  Millions$ 0.380  Millions
Dna Testing Centers Corp  57.91 $ 0.055  Millions$ 0.001  Millions
U S Physical Therapy Inc  57.74 $ 453.911  Millions$ 7.861  Millions
Lifemd Inc   53.31 $ 8.324  Millions$ 0.156  Millions
United Cannabis Corp  48.88 $ 7.245  Millions$ 0.148  Millions
Oncomed Pharmaceuticals Inc  48.49 $ 46.185  Millions$ 0.952  Millions
Nanomix Corp  47.40 $ 0.032  Millions$ 0.001  Millions
Nature s Sunshine Products inc   45.21 $ 364.810  Millions$ 8.069  Millions
Cyclo Therapeutics Inc   43.71 $ 1.585  Millions$ 0.036  Millions
Geovax Labs Inc   39.72 $ 1.406  Millions$ 0.035  Millions
Axim Biotechnologies Inc   39.12 $ 0.196  Millions$ 0.005  Millions

Date modified: 2026-08-30T10:51:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.